Janux Therapeutics Inc (JANX) AI Stock Analysis

• Market Cap: $1.52B
• Dividend Yield: N/A
• Average Volume (3M): 873.06K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.35
• Revenue Growth: 30.99%
• EPS Growth: 4.61%
• Country: US
• Employees: 81
• Sector: Healthcare
• Sector Strength: 77
• Industry: Biotechnology
• EPS (TTM): -1.28
• Shares Outstanding: 59,105,150
• 10 Day Avg. Volume: 770,358
• 30 Day Avg. Volume: 873,063
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 167.13
• Price to Cash Flow (P/CF): -26.50
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $96.78
• Price Target Upside: 275.55% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 11

Janux Therapeutics Inc faces significant challenges with profitability and operational cash flow, which are major factors impacting the stock's attractiveness. The technical indicators suggest bearish momentum, further adding to the concerns. While the recent promising trial results are a positive note, the overall financial and market conditions present considerable risks. Investors should be cautious due to the lack of profitability and ongoing reliance on external financing.

Positive Factors

Clinical Trials

Anticipation of increasing investor attention and stock appreciation when Janux updates the status of the JANX007 clinical trials.

Financial Stability

The company has a strong cash position with approximately $1.03 billion in cash and equivalents.

Technology

Janux's masking technology is showing best-in-class data, which is expected to further validate and gain momentum in clinical-stage programs.

Negative Factors

Clinical Uncertainty

There is real outstanding clinical uncertainty for the program and emerging competitive risks.

Competitive Pressure

Compelling initial set of data from Vir with their dual masked HER2xCD3 and PSMAxCD3 antibodies in a large range of solid tumors, putting competitive pressure on JANX.

Market Performance

The stock has significantly pulled back due to the dissolution of M&A potential in the near term and a competitor putting out competitive data.

Janux Therapeutics Inc Business Overview & Revenue Model

Company Description

Janux Therapeutics Inc (JANX) is a biotechnology company focused on developing next-generation immunotherapies aimed at treating cancer. The company operates within the biopharmaceutical sector and is committed to harnessing its proprietary technology platforms to create therapies that harness the power of the immune system while minimizing potential side effects. Janux's core products include a pipeline of immunotherapeutic candidates designed to target a variety of tumor types.

How the Company Makes Money

Janux Therapeutics Inc makes money primarily through the development and commercialization of its proprietary immunotherapy products. The company's revenue model includes entering into strategic collaborations and partnerships with larger pharmaceutical companies, which provide funding for research and development in exchange for licensing rights and potential milestone payments upon reaching certain clinical or regulatory milestones. Additionally, Janux may earn revenue through royalties on sales of successfully commercialized therapies. The company's earnings are significantly influenced by its ability to advance its drug candidates through clinical trials and ultimately bring them to market.

Janux Therapeutics Inc Financial Statement Overview

Summary

Janux Therapeutics Inc demonstrates strong revenue growth and a robust balance sheet with minimal debt. Despite these strengths, the company is still facing challenges with profitability and cash generation from operations, as indicated by negative net income and operating cash flows. The company remains reliant on financing to support its cash needs.

Income Statement

Janux Therapeutics Inc has shown a significant increase in revenue from $8.08 million in 2023 to $10.59 million in 2024, representing a growth rate of approximately 30.4%. However, the company continues to operate at a net loss with a net profit margin of -651.6% for 2024. The gross profit margin remains high at 100%, but negative EBIT and EBITDA margins indicate operational inefficiencies and high expenses relative to revenue.

Balance Sheet

The company maintains a strong equity base with a stockholders' equity of $1.02 billion, indicating solid foundational support. The debt-to-equity ratio is low at 0.02, suggesting minimal leverage which reduces financial risk. However, the equity ratio at 96.3% shows heavy reliance on equity financing. Return on equity is negative, reflecting ongoing losses.

Cash Flow

Operating cash flow is negative, showing the company is not generating cash from its core operations. Nevertheless, there was an improvement in free cash flow from -$52.43 million in 2023 to -$44.17 million in 2024, reflecting a positive growth rate in free cash flow. The financing cash flow remains strong due to significant cash inflows from financing activities.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
10.59M	8.08M	8.61M	3.64M	0.00
	Gross Profit
10.59M	6.13M	7.77M	3.52M	-13.00K
	EBIT
-98.85M	-72.98M	-67.09M	-32.93M	-4.84M
	EBITDA
-98.85M	-71.02M	-66.25M	-32.82M	-4.83M
	Net Income Common Stockholders
-68.99M	-58.29M	-54.15M	-32.56M	-5.25M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
1.03B	344.03M	327.02M	374.96M	7.81M
	Total Assets
1.06B	380.41M	364.01M	379.82M	16.22M
	Total Debt
23.02M	24.54M	25.30M	194.00K	0.00
	Net Debt
-407.58M	5.34M	-26.12M	-35.39M	-7.81M
	Total Liabilities
38.73M	36.06M	43.27M	13.50M	30.86M
	Stockholders Equity
1.02B	344.35M	320.74M	366.33M	-14.64M
Cash Flow		Free Cash Flow
-44.17M	-52.42M	-49.37M	-18.46M	-4.37M
	Operating Cash Flow
-43.81M	-50.58M	-42.92M	-16.98M	-4.37M
	Investing Cash Flow
-258.02M	-41.19M	58.27M	-340.96M	0.00
	Financing Cash Flow
713.24M	59.55M	500.00K	386.52M	11.52M

Janux Therapeutics Inc Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 25.77
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JANX, the sentiment is Negative. The current price of 25.77 is below the 20-day moving average (MA) of 29.67, below the 50-day MA of 34.24, and below the 200-day MA of 44.34, indicating a bearish trend. The MACD of -1.97 indicates Positive momentum. The RSI at 29.87 is Positive, neither overbought nor oversold. The STOCH value of 8.14 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JANX.

Janux Therapeutics Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	48 Neutral	$6.36B	1.14	-49.00%	2.63%	17.14%	1.39%
ADAP	46 Neutral	$66.06M	―	-273.36%	―	194.23%	45.50%
IMAB	45 Neutral	$53.46M	―	-22.38%	―	―	―
IMTX	45 Neutral	$425.43M	43.42	3.73%	―	188.64%	―
JANX	43 Neutral	$1.52B	―	-10.09%	―	30.99%	4.61%
FATE	42 Neutral	$86.28M	―	-54.21%	―	-78.55%	-0.92%
ALXO	38 Underperform	$27.54M	―	-88.91%	―	―	30.37%

Janux Therapeutics Inc Corporate Events

Janux Therapeutics Reports Promising JANX007 Trial Results

Janux Therapeutics announced promising interim results for its JANX007 clinical program targeting prostate cancer, showing high PSA response rates and robust anti-tumor activity in patients. The Phase 1a trial demonstrated significant efficacy and a well-tolerated safety profile, with notable PSA declines in treated patients. These findings support ongoing development and expansion into further trials, highlighting JANX007’s potential as a differentiated therapy for advanced prostate cancer. The company plans to continue updates as they advance their clinical strategy.